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A simple column chromatographic method for determination of ethambutol (EMB) in pharmaceutical preparations 
containing EMB in combination with other anti-TB drugs is presented. The method involved extraction of EMB into an 
organic solvent. followed by basification and column chromatographic separation on Amberlite CG 50 (100-200 mesh) and 
elution with suitable eluants and estimation at a wavelength of 270 nm. The assay was linear from 25 to 400 µg/ml. The 
relative standard deviations of intra and inter day assays were lower than 5%. Ethambutol was recovered from human urine 
quantitatively and stable for a period of atleast one week in urine stored at-20°C. 
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Ethambutol (EMB), dextro-rotatory isomer of 2,2’- 
(ethylene diimino)-di-1-butanol dihydrochloride is the 
most frequently used for the short course treatment of 
tuberculosis along with rifampicin (RMP), isoniazid 
(INH) and pyrazinamide (PZA)1 and it is 
bacteriostatic to both intracellular and extracellular 
organisms2-8. Many reports have documented the 
efficacy of ethambutol for the treatment of 
bronchopulmonary, urogenital and osteoarticular 
tuberculosis and Mycobacterium avium complex9. 
Successful treatment of tuberculosis requires 
adequate concentration of the chosen drug in 
biological fluids namely blood, cerebrospinal fluid 
(CSF), saliva or urine and in this respect varying 
results have been published for ethambuto10-12. 
Microbiological and gas liquid chromatographic 
(GLC) methods are available for assaying ethambutol 
concentrations in serum and CSF. In microbiological 
assay, when EMB is present along with other drugs in 
plasma, it cannot be assayed without the interference 
of other drugs13. Gas liquid chromatography methods 
using capillary columns are available but they involve 
a series of steps for preparation of the sample before 
analysis and needs internal standard14. Moreover, all 
laboratories cannot afford to have such a sophisticated 
equipment. Hence, pharmacological studies of 
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ethambutol require specific and simple method for 
estimation of the drug in biological fluids containing 
other anti-TB drugs. One such method has been 
standardized and presented in this paper. In addition, 
checking for the stated content of a drug in 
pharmaceutical preparations prior to administering to 
patients; cannot be over-emphasized. Previous 
experience with cycloserine15 and with a syrup 
formulation of isoniazid16 has shown that drug 
preparations could lose their potency when stored. For 
this reason, it is now customary to routinely assay the 
content of anti-tuberculosis drugs in various 
pharmaceutical preparations. 
Ethambutol has been routinely assayed using a 
non-aqueous titration method17,18. It was observed that 
with certain pharmaceutical preparations, the values 
were higher than the stated contents. Another method 
for estimation of ethambutol content in pharmaceutical 
preparations involves reaction with cupric chloride 
and measurement of the absorption in the visible 
range, which is again a time consuming procedure19,20. 
In drug formulations containing EMB in addition to 
other anti-TB drugs, EMB has to be exclusively 
estimated without the interference of other drugs. 
A method that estimates EMB alone by HPLC has 
been reported by Lacroix et al.,21. This was modified 
and this procedure involves ion exchange 
chromatography that enables specific estimation of 
EMB in the presence of other anti-TB drugs. 
Monitoring of EMB concentrations in body fluids 
may be valuable to study drug-drug interactions, if 
any, when co-administered with other antituberculosis 
drugs. It is also possible to specifically estimate EMB 
in urine without the interference of other anti-TB 
drugs. 
The aim of the study was to develop and validate a 
simple method for the estimation of EMB in fixed 
dose combinations (FDCs) containing EMB along 
with other anti-TB drugs and also in biological fluid 
viz., urine, collected from human volunteers after the 
administration of RNTCP regimens which includes 
ethambutol (Ethics committee clearance was 
obtained, informed written consent from each subject 
was obtained). 
Materials and Methods 
Chemicals and reagents- Pure rifampicin, 
ethambutol, pyrazinamide and Amberlite CG-50 
(100-200 mesh) from Sigma Chemical Company, St. 
Louis Missouri, USA, pure isoniazid from May & 
Baker Ltd, Detroit, USA, were used. Ammonia 
(specific gravity 0.91%). absolute ethanol, copper 
sulphate, hydrochloric acid, sodium hydroxide and 
sodium tetraborate were of analytical grade. 
Alkaline ethanol (9 ml of absolute ethanol + 1 ml of 
10 N NaOH), 0.05 M of borate buffer (pH 8). 10% 
aqueous ammonia, ammonical copper sulphate 
reagent (50 mg CuSO4 and 6.33 ml of absolute 
ammonia made up to 100 ml with water) were 
prepared freshly on the day of assay. 
Chromatographic system - Amberlite CG-50 ( 10 g)- 
weakly acidic cation exchanger (mesh size 100-200) 
was washed 5 times with double distilled water and 
allowed the beads to swell in 50 ml of 1 N. NaOH over 
night for basification. The soaking of the resin in 
NaOH should not exceed 24 hr. The p H of the resin 
was broughtdown to 7.5-9.5 by washing with water. 
Then, the resin was packed in the column of 1 cm 
diam. to a height of 7.5 cm from the tip plugged with 
cotton. The resin was prevented to dry by keeping 
water level above the resin bed. Plasticine was used to 
control the flow rate. 
Preparation of standard solution -A stock 
solution (1mg/ml) was prepared by dissolving EMB 
in 0.1 N HCl. Ethambutol standards were prepared in 
serial concentrations ranging from 25 to 400µg/ml in 
0.1N HCl as well as normal pooled urine, which 
contained RMP (250µ/ml), INH (l00µg/ml) and 
PZA (600µg/ml). From the standard graph, the 
quantification of EMB in FDCs as well as in urine 
collected from the patients after the drug 
administration was carried out. 
Formulation containing EMB along with other 
anti-TB drugs- A total of 15 tablets with EMB alone 
(ethambutol hydrochloride-single drug-200, 400 and 
800 mg of each), 4 tablets with RMP and INH 
(Macox plus 150-double drug formulation without 
EMB), 6 tablets containing EMB and INH 
(Combunex 800-double drug formulation without 
RMP), 11 tablets containing RMP, EMB and INH 
(AKuriT 3-triple drug formulation-without PZA) and 
26 tablets containing RMP, EMB, INH and PZA 
[AKuriT 4, and AKuriT FD-Quadruple drug 
formulations containing all the 4 drugs of 2 different 
brands; (17 and 9 of each)] were processed by the 
method standardised currently. In brief, the weight of 
each tablet was noted, crushed and made up to a 
known volume with 0.1 N HCl and filtered. Suitable 
dilutions were made so that the concentrations of 
EMB from each tablet was around 400 µg/ml. To 5 
ml of sample, 15 ml of chloroform was added and 
kept on gyrotary shaker for 30 min. Four ml of 
chloroform free phase was basified with 0.4 ml of 
alkaline ethanol. Loaded 2 ml of the mixture onto the 
packed column. The loaded columns were washed 
sequentially with 3-5 ml of water, 5.0 ml of ethanol, 
15 ml of borate buffer (0.05 M; p H 8.0) and 15 ml of 
10% aqueous ammonia solution. Two aliquots of 
ammonia eluates (5 ml) were collected, centrifuged 
for 5 min and to 2.2 ml of the eluate, 0.8 ml of 
ammonical copper sulphate solution was added and 
the optical densities were recorded at 270 nm using 
lcm cells, in a unicam spectrophotometer. 
EMB in urine- Ethambutol was estimated by this 
procedure in urine collected over a period of 0-8 hr 
from 12,13,12 patients suffering from HIV, TB, 
HIV/TB respectively. The patients investigated were 
receiving RNTCP regimen containing RMP (450 mg), 
EMB(1200 mg), INH (600 mg) and PZA(1500 mg). 
The study was presented before the ethics committee 
and clearance was obtained. In addition written 
consent was obtained from study subjects. This is just 
to check for the application of this methodology in the 
estimation of EMB in urine in the presence of other 
Sensitivity- The sensitivity of the method was 
estimated after setting up serial concentrations of 
EMB (50-400 µg/ml). 
Precision - The precision of the method was 
evaluated by analyzing pooled human urine samples 
(These are normal urine samples collected and pooled 
drugs. 
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from volunteers (staff members) from TRC. Since the 
volunteers were willing to give the samples, ethics 
committee clearance was felt unncessary.) containing 
four different concentrations of EMB. The inter and 
intra-day variations were determined by assaying each 
sample in triplicate for 3 days. 
Recovery- For the recovery experiment, the 
pooled human urine samples containing previously 
determined concentrations of EMB, were spiked with 
50, 100 and 200 µg/ml of EMB and assayed. The 
percentage of recovery was calculated by dividing 
sample differences with the added concentrations. 
Stability- Stability of EMB in urine was 
evaluated by analyzing pooled human urine samples 
containing 50, 100,200 and 400 µg/ml of EMB along 
with other anti-TB drugs in the proportions mentioned 
above. The samples were prepared and stored for 10 
days at -20° C. The stability was checked on 0, 1,4,7 
and 10 days after storage. 
Results and Discussion 
Ethambutol is widely used for the treatment of 
mycobacterial diseases. It was developed in response 
to increasing bacterial resistance to the first line 
agents22. Ethambutol, being bacteriostatic, is rapidly 
taken up by the organism and inhibits mycobacterial 
cell wall synthesis 23. Also, tuberculosis requires 
effective chemotherapy, which can be achieved with 
regimens consisting of a number of drugs given either 
individually or in FDC(s) containing RMP, INH and 
PZA, in addition to EMB. In the routine management 
of patients with this drug as in the case with other 
drugs, it is necessary to have information on the levels 
attained in biological fluids. Several HPLC and GLC- 
mass spectrometry methods have been reported to 
measure and to quantify EMB levels in plasma and 
urine14. The methodologies described in these reports 
are complex and lengthy involving pre-preparation of 
the samples and the usage of expensive columns for 
GLC. Chemical methods are tedious, time consuming 
and are not efficiently sensitive. A microbiological 
assay 13 has been reported that it is time consuming as 
results are available only after 48 hr. Taking the leads 
from the earlier workers, a procedure for EMB in 
urine has been standardised. The method described in 
this report presents the results on the standardisation 
of ethambutol in formulations and biological fluid, 
defining the optimal conditions. It has been found to 
be very simple, satisfactory and reproducible. The 
methodology also defined several essential criteria to 
be fulfilled for the satisfactory results. For example, 
use of Amberlite CG-50 with 100-200 mesh size 
seem to be highly essential. The present method has 
the advantages of being rapid, involving simple steps 
like dilution and extraction into chloroform, 
adsorption of EMB onto the basified column leaving 
behind other drugs, and further, elution with suitable 
solvent system without any loss of analyte at any step. 
The p H has been found highly critical at which the 
elution was maximal and other anti-TB drugs did not 
interfere. The time taken for chromatography was also 
shorter. 
Figure 1 gives mean values for EMB in 0.1 N HCI 
and pooled normal urine (collected from different 
volunteers). The concentration standards ranged from 
50 to 400 µg/ml in 0.1 N HCI (7 occasions) or pooled 
normal (drug free) urine (10 occasions). Under these 
operating conditions, the lowest detection limit was 
25 µg/ml. Table 1 gives the per cent recovery of EMB 
from pooled normal human urine and was found to be 
90-100% in the presence of other anti-TB drugs. The 
sensitivity of the method. indicated that the lowest 
concentration (25 µg/ml) of EMB could be estimated 
by this procedure. 
Ethambutol in HCI or urine was estimated in the 
presence of other anti-TB drugs (RMP, INH and 
PZA) and these drugs did not interfere and was 
specific for EMB. 
The method described was applied for 
determination of EMB excreted in urine upto a period 
of 8 hr collected from the patients HIV (12), TB (13) 
and HIV/TB (12). who were given RNTCP regimen 
containing RMP, EMB, INH and PZA. Based on the 
excretion of the drug in urine (0-8 hr), % dose 
excreted was determined for EMB. The specificity in 
relation to other anti-TB drugs was a matter of 
concern, since the assay was based on the adsorption 
of EMB onto Amberlite CG 50 (100-200 mesh size) 
under basic conditions where other anti-tuberculosis 
Fig. 1 - Ethambutol in 0.1 N HCI and urine 
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Table 1 -Recovery of EMB from Urine 
Concentration Added Total EH* EHR* EHRZ* 
estimated concen concen Concen % Concen % Concen % 
already tration tration tration tration tration 
(µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
50 
100 
200 
50 
100 
200 
50 
100 
200 
50 
50 
50 
100 
100 
100 
200 
200 
200 
100 104.3 
150 135.2 
250 255.8 
150 157.3 
200 182.5 
300 296.0 
250 256.8 
300 296.7 
400 396.7 
104 
90 
103 
105 
91 
99 
103 
99 
99 
98.1 
146.2 
257.1 
160.6 
196.8 
315.5 
260.1 
292.1 
395.8 
98 
97 
103 
105 
98 
105 
104 
97 
99 
94.0 
147.2 
260.1 
153.8 
204.0 
311.3 
247.3 
305.6 
41 1.8 
94 
98 
104 
102 
102 
103 
99 
102 
103 
*H-100 µg/ml, R-250 µg/ml. Z-600 µg/ml 
Table 2-Stability of EMB in urine 
Optical Density 
0 1st 4th 7th 10th Concentration 
(µg/ml) day day day day day 
50 0.154 0.110 0.148 0.142 0.152 
100 0.314 0.302 0.259 0.300 0.276 
200 .0.650 0.669 0.609 0.629 0.663 
400 1.332 1.218 1.218 1.242 1.346 
drugs namely RMP, INH and PZA did not interfere. 
The % dose of EMB excreted in urine was almost 
similar in patients under investigation. However, this 
needs to be confirmed on a larger sample size. 
Differential concentrations of EMB were assayed 
in the presence of other anti-TB drugs on 0, 1, 4, 7 
and 10 days after storage. The results showed that 
there was no deterioration of EMB even after storage 
upto 10 days (Table 2) and was 80-100% stable. 
Since for TB, monotherapy is not advocated, and 
the patients are always given combination regimens, 
checking for both the quality of the drug as well as for 
the presence of exact quantity of the stated content in 
pharmaceutical preparations, are highly essential, in 
turn, to assess the bioavailability of the drug in human 
subjects. This could be achieved only after applying 
reliable, accurate and specific method to quantitate 
the drug in the formulation without the interference of 
other drugs. It is now possible to estimate in urine 
containing EMB in addition to other drugs and their 
metabolites. Therefore, fixed dose formulations 
containing EMB alone and in combination with other 
anti-TB drugs need to be examined by this method to 
validate the specificity. A total of 15 tablets of 
ethambutol hydrochloride containing EMB alone, 6 
tablets of combunex 800 containing INH in addition 
to EMB, 11 tablets of AKuri T3 containing RMP, 
INH in addition to EMB, 17 tablets of AKuri T4 
containing RMP, INH, PZA and EMB and 9 tablets of 
AKuriT FD containing RMP, INH, PZA along with 
EMB, were processed by this method to quantify 
EMB (Table 3). 
The results obtained in urine excreted during 0-8 hr 
in patients administered RNTCP regimen showed that 
there was a significant difference in the % dose of 
EMB excreted between TB (control) and HIV group. 
However, TB vs HIV/TB and HIV vs HIV/TB were 
not significant (Table 4). 
Based on the findings obtained with different 
formulations (FDCs) as well as with urine, it was 
concluded that EMB could be quantitatively assayed 
without the interference of other anti-TB drugs. 
Similarly, EMB could be determined in urine samples 
excreted over 0-8 hr collected from human subjects 
who were administered EMB along with other drugs. 
Dissolution of the drugs in pharmaceutical 
preparations, which is an indirect measure of the drug 
release in stomach, was carried out using the standard 
equipment. Tablets containing EMB alone were run 
through the dissolution apparatus and the release of 
EMB was estimated by the present procedure to check 
for completeness of release. Similarly, FDC 
containing 2, 3 or 4 drugs (containing EMB in 
addition to other drugs), were also processed by the 
dissolution apparatus and assayed for EMB. 
Thus, this methodology is highly useful to assess 
the bioavailability of EMB either in pharmaceutical 
preparations or in biological fluid in the presence of 
other anti-TB drugs. The present method has the 
advantages of being simple and rapid. The technique 
involved steps like dilution and extraction into 
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Table 3 -Estimation of EMB in tablets 
[Values are mean ± SD] 
Ethambutol hydrochloride Macoxplus Comunex AkuriT3f AkuriT4f AkuriT 
(RH) (EH) . (ERHZ) 
201.42 392.66 806.57 801.67 273.75 275.42 264.85 
± ± ± ± ± ± ± 
6.50 14.69 34.69 29.25 8.02 7.76 13.04 
EMB alone (mg) EMB in FDCs (mg) 
(E) 150 800e (ERH) (ERHZ) FDg 
200a 400b 800c 
- 
Acceptable range - 
a190-210 mg: e760.0-840.0 mg; 
b380-420 mg: f261.2-288.7 mg; 
c760-840 mg; g253.6-280.3 mg 
Table 4- % dose of EMB excreted in urine of patients with TB. 
HIV and HIV/TB 
Group Mean ± S.D. 
TB (n=13) 41.5 ± 13.4 
HIV (n= 12) 22.4 ± 10.8 
HIV/TB (n=12) 30.9 ± 13.5 
TB VS HIV (p < 0.05)-S; TB VS HIV/TB - NS; HIV VS HIV/TB - 
NS 
chloroform, adsorption onto the column and elution 
with suitable solvent system and during these steps 
there was no loss of the analyte. The p H is highly 
critical at which the elution is maximal and other anti- 
TB drugs do not interfere and the results are available 
with shorter chromatographic adsorption and clution 
time. 
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